Biomedicines (Nov 2022)

Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients

  • Andrea Di Lorenzo,
  • Simona Tedde,
  • Pier Giorgio Pace,
  • Laura Campogiani,
  • Lorenzo Ansaldo,
  • Alessandra Lodi,
  • Marta Zordan,
  • Filippo Barreca,
  • Federica Caldara,
  • Benedetta Rossi,
  • Alessandra Imeneo,
  • Grazia Alessio,
  • Angela Maria Antonia Crea,
  • Davide Checchi,
  • Vincenzo Malagnino,
  • Elisabetta Teti,
  • Luigi Coppola,
  • Raffaele Palmieri,
  • Francesco Buccisano,
  • Massimo Andreoni,
  • Loredana Sarmati,
  • Marco Iannetta

DOI
https://doi.org/10.3390/biomedicines10112788
Journal volume & issue
Vol. 10, no. 11
p. 2788

Abstract

Read online

Lymphopenia has been consistently reported as associated with severe coronavirus disease 2019 (COVID-19). Several studies have described a profound decline in all T-cell subtypes in hospitalized patients with severe and critical COVID-19. The aim of this study was to assess the role of T-lymphocyte subset absolute counts measured at ward admission in predicting 30-day mortality in COVID-19 hospitalized patients, validating a new prognostic score, the T-Lymphocyte Subset Index (TLSI, range 0–2), based on the number of T-cell subset (CD4+ and CD8+) absolute counts that are below prespecified cutoffs. These cutoff values derive from a previously published work of our research group at Policlinico Tor Vergata, Rome, Italy: CD3+CD4+ p p p = 0.003). Survival analysis showed that patients with a TLSI > 0 had an increased risk of death compared to patients with a TLSI = 0 (hazard ratio: 2.83, p < 0.0001). The TLSI was confirmed as an early and independent predictor of COVID-19 in-hospital 30-day mortality.

Keywords